Belizario 2003.

Methods	Design: parallel group randomized trial Duration of study: second half of 1998 Duration of follow‐up: 7–14 days
Participants	Country: Republic of the Philippines Setting: school Number included in study: 784 Age: 6–12 years Sex: not reported Inclusion criteria: boys or girls; aged 6–12 years; informed consent; A lumbricoides or T trichiura (or both) eggs in stool samples; and compliance with protocol, requiring stool samples at the specified times after treatment Exclusion criteria: previous hypersensitivity reaction to benzimidazole, ivermectin, diethylcarbamazine, or any related compound; other helminths; without the target helminths listed; diarrhoea disease; receipt of any anthelmintic in the 2 weeks before enrolment; receipt of an anthelmintic during the study period; and concomitant infection or underlying disease compromising evaluation of the response to the medications being studied Lost at follow‐up: 29 (3.7%) Number positive for A lumbricoides: 528 Number included in review: 306
Interventions	Treatment strategy: screening and treat all included participants Group 1: albendazole 400 mg single dose + placebo (n = 99) Group 2: ivermectin 200 μg/kg bodyweight + placebo (n = 102) Group 3: albendazole 400 mg + ivermectin 200 μg/kg bodyweight (n = 105) Group 4: diethylcarbamazine 150 mg + placebo (not included) Group 5: albendazole 400 mg + diethylcarbamazine 150 mg (not included)
Outcomes	Outcomes included:Ascaris prevalence pre‐ and post‐treatment, cure rate, pre‐ and post‐treatment AM epg, ERR Outcomes not included in review: efficacy of anthelmintic treatment for Trichuris; efficacy of diethylcarbamazine and albendazole + diethylcarbamazine for A lumbricoides.
Notes	Diagnostic technique: Kato‐Katz Funding support: World Health Organization
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Details not reported.
Allocation concealment (selection bias)	Unclear risk	Details not reported.
Blinding of participants and personnel (performance bias) All outcomes	High risk	Quote: "Placebo resembling albendazole was used together with the one‐drug treatments in order to make it appear that all pupils were receiving a combination of two drugs." Comment: ivermectin not blinded.
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Details not reported.
Incomplete outcome data (attrition bias) All outcomes	Low risk	29 (3.7%) participants lost at follow‐up and not included in analysis.
Selective reporting (reporting bias)	High risk	Adverse events not reported.
Other bias	Low risk	No obvious source of bias.